Eli Lilly and
(LLY) ✕
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
undefined
undefined%
At close: undefined
762.54
-0.20%
Pre-market Jan 07, 2025, 05:38 AM EST
Eli Lilly and Revenue Breakdown
Quarter | Sep 30, 2024 | Mar 31, 2024 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 | Mar 31, 2014 | Dec 31, 2013 | Sep 30, 2013 | Jun 30, 2013 | Mar 31, 2013 | Dec 31, 2012 | Sep 30, 2012 | Jun 30, 2012 | Mar 31, 2012 | Jun 30, 2011 | Mar 31, 2011 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunology Revenue | 1.19B | 834.00M | 986.90M | 928.50M | 777.80M | 866.40M | 796.50M | 748.10M | 1.00B | 785.40M | 613.90M | 627.10M | 548.30M | 585.80M | 454.60M | 456.10M | 334.70M | 894.50M | 966.90M | 861.30M | 922.60M | 759.00M | 887.90M | 869.90M | 893.70M | 964.40M | 1.48B | 1.88B | 2.00B | 1.85B | 2.03B | 1.82B | 1.82B | 1.90B | 2.65B | 53.60M |
Immunology Revenue Growth | +42.17% | -15.49% | +6.29% | +19.38% | -10.23% | +8.78% | +6.47% | -25.55% | +27.95% | +27.94% | -2.10% | +14.37% | -6.40% | +28.86% | -0.33% | +36.27% | -62.58% | -7.49% | +12.26% | -6.64% | +21.55% | -14.52% | +2.07% | -2.66% | -7.33% | -35.05% | -20.94% | -6.31% | +8.42% | -8.98% | +11.86% | -0.48% | -4.16% | -28.27% | +4851.12% | n/a |
Neuroscience Revenue | 351.80M | 389.10M | 1.77B | 387.20M | 360.50M | 373.20M | 389.90M | 397.70M | 450.20M | 512.20M | 465.40M | 470.70M | 422.50M | 463.50M | 426.70M | 452.70M | 393.10M | 643.70M | 721.70M | 724.50M | 763.90M | 725.30M | 868.50M | 882.40M | 858.40M | 764.30M | 874.40M | 821.80M | 808.10M | 764.20M | 839.20M | 791.70M | 846.80M | 803.90M | 825.80M | 2.41B |
Neuroscience Revenue Growth | -9.59% | -77.99% | +356.64% | +7.41% | -3.40% | -4.28% | -1.96% | -11.66% | -12.10% | +10.06% | -1.13% | +11.41% | -8.85% | +8.62% | -5.74% | +15.16% | -38.93% | -10.81% | -0.39% | -5.16% | +5.32% | -16.49% | -1.58% | +2.80% | +12.31% | -12.59% | +6.40% | +1.70% | +5.74% | -8.94% | +6.00% | -6.51% | +5.34% | -2.65% | -65.66% | n/a |
Oncology Revenue | 2.23B | 1.81B | 1.75B | 1.67B | 1.36B | 1.29B | 1.37B | 1.35B | 1.41B | 1.55B | 1.37B | 1.33B | 1.27B | 1.20B | 1.15B | 1.20B | 1.01B | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 59.50M | 839.90M |
Oncology Revenue Growth | +23.30% | +3.60% | +4.55% | +23.23% | +4.85% | -5.51% | +1.16% | -3.78% | -9.52% | +13.25% | +2.91% | +5.11% | +5.58% | +4.72% | -4.16% | +18.22% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -92.92% | n/a |
Other Product Revenue | 53.20M | 41.30M | 42.90M | 51.00M | 52.80M | 66.60M | 80.10M | 98.10M | 88.80M | 64.60M | 107.50M | 97.00M | 97.60M | 174.70M | 119.20M | 123.30M | 113.40M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Product Revenue Growth | +28.81% | -3.73% | -15.88% | -3.41% | -20.72% | -16.85% | -18.35% | +10.47% | +37.46% | -39.91% | +10.82% | -0.61% | -44.13% | +46.56% | -3.33% | +8.73% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Revenue by Geography
Quarter | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
China Revenue | 1.54B | 1.45B | 1.66B | 1.12B | 3.77B | 4.23B | 3.94B | 3.77B | 3.94B | 4.51B | 4.34B | 4.26B |
China Revenue Growth | +5.98% | -12.56% | +48.75% | -70.33% | -11.02% | +7.30% | +4.65% | -4.45% | -12.49% | +3.88% | +1.85% | n/a |
Europe Revenue | 6.17B | 4.30B | 4.78B | 4.19B | 2.55B | 2.49B | 2.42B | 2.33B | 2.03B | 2.03B | 3.82B | 3.78B |
Europe Revenue Growth | +43.62% | -10.00% | +14.07% | +64.38% | +2.16% | +3.06% | +3.81% | +14.65% | +0.30% | -46.95% | +0.97% | n/a |
Japan Revenue | 1.67B | 1.75B | 2.37B | 2.58B | 3.28B | 3.96B | 3.72B | 3.62B | 3.88B | 3.95B | n/a | n/a |
Japan Revenue Growth | -4.28% | -26.18% | -8.37% | -21.35% | -16.97% | +6.24% | +2.94% | -6.89% | -1.60% | n/a | n/a | n/a |
Other Foreign Countries Revenue | 2.95B | 2.85B | 2.70B | 2.42B | 12.72B | n/a | 12.79B | 11.51B | 10.10B | 9.13B | n/a | n/a |
Other Foreign Countries Revenue Growth | +3.30% | +5.54% | +11.54% | -80.96% | n/a | n/a | +11.11% | +13.95% | +10.55% | n/a | n/a | n/a |
United States Revenue | 21.79B | 18.19B | 16.81B | 14.23B | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
United States Revenue Growth | +19.80% | +8.20% | +18.14% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
Quarter | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selling, General, and Administrative Revenue | 2.10B | 2.12B | 1.95B | 1.92B | 1.80B | 1.93B | 1.75B | 1.64B | 1.61B | 1.63B | 1.56B | 1.59B | 1.58B | 1.69B | 1.58B | 1.55B | 1.57B | 1.45B | 1.55B | 1.70B | 1.41B | 1.59B | 1.52B | 1.86B | 1.62B | 1.65B | 1.50B | 1.78B | 1.56B | 1.71B | 1.54B | 1.79B | 1.57B | 1.62B | 1.47B | 1.80B | 1.58B | 1.64B | 1.52B |
Selling, General, and Administrative Revenue Growth | -0.83% | +8.46% | +1.43% | +6.69% | -6.31% | +10.07% | +6.45% | +1.80% | -0.67% | +4.31% | -2.14% | +0.89% | -6.39% | +6.96% | +1.42% | -0.97% | +8.32% | -6.52% | -8.75% | +20.24% | -10.97% | +4.56% | -18.50% | +15.15% | -2.24% | +10.25% | -15.75% | +14.46% | -8.90% | +10.53% | -13.71% | +14.35% | -3.53% | +10.09% | -18.04% | +14.13% | -3.65% | +7.34% | n/a |
Research and Development Revenue | 2.73B | 2.71B | 2.52B | 2.56B | 2.41B | 2.36B | 1.99B | 2.00B | 1.80B | 1.78B | 1.61B | 1.96B | 1.71B | 1.67B | 1.68B | 1.84B | 1.47B | 1.39B | 1.39B | 1.58B | 1.38B | 1.40B | 1.23B | 1.45B | 1.34B | 1.33B | 1.18B | 1.47B | 1.32B | 1.25B | 1.24B | 1.45B | 1.24B | 1.34B | 1.22B | 1.44B | 1.14B | 1.17B | 1.04B |
Research and Development Revenue Growth | +0.84% | +7.47% | -1.56% | +6.38% | +2.23% | +18.71% | -0.54% | +10.70% | +1.18% | +10.67% | -17.83% | +14.66% | +2.16% | -0.71% | -8.34% | +25.43% | +5.41% | -0.14% | -11.97% | +14.52% | -1.52% | +13.95% | -15.36% | +8.23% | +0.77% | +13.27% | -20.11% | +11.66% | +5.48% | +1.02% | -14.64% | +17.32% | -7.45% | +9.41% | -15.45% | +26.31% | -2.23% | +12.53% | n/a |